New Online Education Offerings
Uterine mesenchymal neoplasms: new and evolving entities
Cervical Cancer Survivorship: A Patient's Perspective
Palliative Care in Disaster and Conflict Settings
Home > Educational Webinars
Recently Recorded
Uterine mesenchymal neoplasms: new and evolving entities
In this session, we will review new and evolving uterine mesenchymal entities as well as biomarker and molecular assays to aid in these diagnoses. Additionally, appropriate diagnostic terminology will be covered in the absence of accessible immunohistochemistry and molecular testing.
This webinar is complimentary for IGCS members.
Brooke Howitt, MD
Associate Professor of Pathology
Stanford University School of Medicine
USA
Adrian Suarez, MD
Moderator
Surgical Pathology Director
The Ohio State University Wexner Medical Center
USA
Palliative Care in Disaster and Conflict Settings
Political and ethnic conflict, and geological and climatic disasters, result in suffering on a massive scale, particularly in low- and middle-income countries with fragile health care systems. Palliative care, defined most often as a response to physical, psychological, social, or spiritual suffering of those with “life-limiting illness,” is crucial for those with such illnesses in humanitarian settings. But those without life-limiting illnesses also suffer severely, due, for example, to gender-based violence or to witnessing and fleeing from extreme violence. This webinar will explore how, in humanitarian settings, palliative care can and should be true to its mission of responding to suffering without the constraint of focusing only on those with life-limiting illnesses.
This webinar is complimentary for IGCS members.
Eric L. Krakauer, MD, PhD
Director, Program in Global Palliative Care
Associate Professor of Medicine
Associate Professor of Global Health & Social Medicine
Harvard Medical School
USA
Annekathryn “AK” Goodman, MD, MS, MPH
Professor of Obstetrics, Gynecology and Reproductive Biology
Harvard Medical School
USA
Nahla Gafer, MD
Clinical Oncologist & Head Palliative Care Unit
Khartoum Oncology Hospital
Director, Palliative Care Continuous Education
Comboni College of Science and Technology
Sudan
Peter Grant, MD
Moderator
Assoc Professor, University of Melbourne
Gynaecological Oncologist, Western Health, Melbourne
Australia
Anisa Mburu, MD
Moderator
Gynecologic Oncologist
Aga Khan Hospital and International Cancer Institute
Kenya
The Evolving Treatment Landscape for The Management of Endometrial Cancer
IGCS and Eisai welcomes gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to view the first presentation from the An Evolving Frontier - Understanding Novel Treatment Options for The Management of Advanced Stage or Recurrent Endometrial Cancers Industry Supported Symposium presented at the IGCS 2023 Annual Global Meeting in Seoul, Korea.
Part 1: The Evolving Treatment Landscape for The Management of Endometrial Cancer
Released February 2024
Ramez N. Eskander, MD
UC San Diego School of Medicine
USA
Part 2: Immunotherapy After Immunotherapy, What Are The Opportunities for Immune Check-Point Inhibition Re-challenge and The Role of Pembrolizumab/Lenvatinib
Released June 2024
Stephanie Lheureux, MD, PhD
Princess Margaret Cancer Centre
Canada
Eisai have sponsored this initiative with IGCS and had no input into or influence over the content.
Cervical Cancer Survivorship:
A Patient's Perspective
In this IGCS Advances & Updates special presentation, Linda Ryan, a metastatic recurrent cervical cancer survivor and patient research advocate shares her story and experience with clinical trials. Linda is joined by her gynecologic oncologist, Dr. Shannon Westin, a professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas. Listen to Linda and Dr. Westin as they discuss recent approval and therapeutic options for patients with recurrent cervical cancer.
Emerging Data in platinum resistance advanced ovarian cancer
Lainie P. Martin, MD
Leader, Gynecology/Oncology Program
Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Associate Professor of Obstetrics and Gynecology
University of Pennsylvania Perelman School of Medicine
USA
David O’Malley, MD
Ohio State University Comprehensive Cancer Center-James Cancer Hospital &
Solove Research Institute Professor
Director, Division of Gynecologic Oncology
Co-Director, Gyn Oncology Phase I Program
USA
Selinexor in Maintenance Therapy After Systemic Therapy for Patients with p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma: XPORT-042 - Trial in Progress
Robert Coleman, MD, FACOG, FACS
Chief Medical Officer
Vaniam Group
USA
Floor Backes, MD
Moderator
Director of Clincial Research and Fellowship Director for the Division of Gynecologic Oncology
The Ohio State University Wexner Medical Center
James Comprehensive Cancer Center
USA
Available as a Podcast!
Would you rather listen to this recording? Listen on Education360 Learning Portal or the streaming services below!
Immunotherapy and its impact on overall survival in patients with recurrent endometrial cancer
Matthew A. Powell, MD
Professor, Div Gyn Oncology
Chair Uterine Corpus Committee
National Cancer Institute sponsored NRG Oncology
Washington University School of Medicine
USA
R. Wendel Naumann, M.D.
Director of Gynecologic Oncology Research
Associate Medical Director of Clinical Trials
Levine Cancer Institute – Hall Gynecologic Oncology Center
USA
Newly Opened Phase 3 Study for Low Grade Serous Ovarian Cancer
Rachel Grisham, MD
Section Head Ovarian Cancer
Director, Gynecologic Medical OncologyMemorial Sloan Kettering Cancer Center
USA
Susana Banerjee, MBBS, MA, PhD, FRCP
Consultant Medical Oncologist
Research Lead Gynaecology Unit
The Royal Marsden
Professor in Women’s Cancers,Institute of Cancer Research, London
UK
Dr. Rachel Grisham and Dr. Susana Banerjee discussed details about a potential clinical trial for your patients. The RAMP 301 trial is evaluating the novel combination of avutometinib + defactinib versus investigator’s choice of therapy in patients with recurrent low grade serous ovarian cancer.
